Clinical Trials Logo

Clinical Trial Summary

To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In particular, this surveillance will collect only information of occurrence state and treatment methods on bone marrow depression (neutropenia), which is specified as a safety specification, as well as on tumor flare, for which attention should be called. 1. Planned registration period 1.5 years 2. Planned surveillance period 3 years from the start of this survey


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04618081
Study type Observational
Source Celgene
Contact BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone 855-907-3286
Email Clinical.Trials@bms.com
Status Recruiting
Phase
Start date December 18, 2020
Completion date March 27, 2025